A Phase IV, Multinational, Open-Label, Single-Arm Umbrella Study Evaluating the Efficacy and Safety of Subcutaneous Tocilizumab as Monotherapy or in Combination with Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) Over 24 Weeks in Adult Patients With Moderate to Severe Rheumatoid Arthritis
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms TOZURA
- 17 Jun 2017 Results (n=1804) assessing the efficacy and safety of subcutaneous tocilizumab monotherapy or combined with a Csdmard in patients with rheumatoid arthritis, presented at the 18th Annual Congress of the European League Against Rheumatism.
- 25 Aug 2016 New trial record